Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by bball67on Jun 29, 2022 12:41pm
159 Views
Post# 34790849

RE:Series 1 Shares - 70million Consolidable or not

RE:Series 1 Shares - 70million Consolidable or notI will take a shot at your question. There will be no trickery. Let's say in November 2022, Promis decides to raise $30M new equity in a secondary offering to fund clinical trials and operations etc. let's say the offering is at $20 per share US. The Boston Group of invididuals have $20,000,000 of debt remaining, assuming no interest has been declared. Their debt must be converted into common shares because the $30,000,000 is being raised per the agreement that the debt must be converted if $30M in equity is being raised. Promis would issue the Boston Group 1,000,000 shares @ $20US to satisfy the debt. So, in effect this activity would be subject to the 1 for 60 reverse split. However, they would not benefit from share price appreciation from now until an offering is made which makes me think it might be next on the list after a NASDAQ listing. 
<< Previous
Bullboard Posts
Next >>